News Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Delayed Nasdaq Stockholm Other stock markets 05:30:01 26/06/2024 pm IST			5-day change	1st Jan Change
1.445 ^SEK	-2.36%		+5.09%	-68.31%

11/06	Elicera Therapeutics Enters A Preclinical Collaboration Agreement with China Medical University for the Development of Elc-201	CI
29/05	Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BioStock: Elicera teams up with China Medical University for cancer study	17/06	AQ
Elicera Therapeutics Enters A Preclinical Collaboration Agreement with China Medical University for the Development of Elc-201	11/06	CI
BioStock: Elicera's first clinical CAR T-Cell study CARMA set to begin	29/05	AQ
Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA	29/05	CI
Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2024	27/05	AQ
Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	27/05	CI
Elicera Therapeutics publishes the annual report for 2023	16/04	AQ
Nomination committee proposes CMC specialist to Elicera's board of directors	28/03	AQ
Elicera Therapeutics AB Announces Director Changes	28/03	CI
Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB	22/03	AQ
Elicera Therapeutics announces outcome in rights issue	11/03	AQ
BioStock: Elicera collaborates with US cancer centre to evaluate iTANK	07/03	AQ
Elicera enters agreement with prominent US Cancer Center to evaluate the use of iTANK in T-cell receptor therapies	06/03	AQ
Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies	06/03	CI
Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue	04/03	AQ
The subscription period in Elicera Therapeutics' rights issue of units starts today	23/02	AQ
Elicera Therapeutics publishes prospectus in connection with rights issue of units	21/02	AQ
BioStock: Full speed ahead for Elicera in 2024	19/02	AQ
Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024	16/02	AQ
Elicera Therapeutics AB to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1	16/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Summary

Filters